8-K

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 OR 15(d) of the

Securities

Exchange Act of 1934

Dateof Report (Date of earliest event reported): November 27, 2024 (November 26, 2024)

VivosTherapeutics, Inc.

(Exactname of registrant as specified in its charter)

7921Southpark Plaza, Suite 210

Littleton,Colorado 80120

(Addressof principal executive offices) (Zip Code)

(866)908-4867

(Registrant’stelephone number, including area code)

N/A

(Formername or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item5.07 Submission of Matters to a Vote of Security Holders.

On November 26, 2024, Vivos Therapeutics, Inc. (the “Company”) conducted its 2024 annual meeting of stockholders (the “Annual Meeting”). The number of shares of common stock of the Company entitled to vote at the Annual Meeting was 4,765,300 shares outstanding as of the October 4, 2024 record date (the “Voting Stock”). No other shares of the Company’s capital stock were entitled to vote at the Annual Meeting.

The number of shares of Voting Stock present or represented by valid proxy at the Annual Meeting was approximately 2,695,565 shares of Voting Stock, constituting a quorum. At the Annual Meeting, the Company’s stockholders:

The following is a tabulation of the voting on the proposals presented at the Annual Meeting:

ProposalNo. 1 – Election of Directors

R. Kirk Huntsman, Dr. Ralph Green, Anja Krammer, Mark Lindsay, Leonard Sokolow and Dr. Matthew Thompson were each elected as a director to serve for a one-year term that expires at the 2025 annual meeting of stockholders or until a successor is elected and qualified or until her or his earlier death, incapacity, removal or resignation. The voting results were as follows:

ProposalNo. 2 – Approval of Company’s Proposed 2024 Omnibus Equity Incentive Plan and Contingent Awards

Approved and adopted the Company’s proposed 2024 Omnibus Equity Incentive Plan (the “2024 Plan”) and the issuance of contingent awards under the 2024 Plan to certain Company officers, employees and consultants. The voting results were as follows:

ProposalNo. 3 – Ratification of the appointment of independent registered public accounting firm

Appointment by the Company’s audit committee of Moss Adams LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified. The voting results were as follows:

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.